Effect of basic fibroblast growth factor on radiation-induced oral mucositis in male Syrian hamsters

References

• Beaven AW, Shea TC. 2007. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. Drugs Today. 43:461–473.
   PubMed Web of Science ®Google Scholar
• Bonomi M, Batt K. 2015. Supportive management of mucositis and metabolic derangements in head and neck cancer patients. Cancers (Basel). 7:1743–1757.
   PubMed Web of Science ®Google Scholar
• DeLapp NW, Dieckman DK. 1990. Effect of basic fibroblast growth factor (bfgf) and insulin-like growth factors type i (igf-i) and type ii (igf-ii) on adult human keratinocyte growth and fibronectin secretion. J Invest Dermatol. 94:777–780.
   PubMed Web of Science ®Google Scholar
• Doi H, Fujiwara M, Suzuki H, Niwa Y, Nakayama M, Shikata T, Odawara S, Takada Y, Kimura T, Kamikonya N, et al. 2015. Polaprezinc reduces the severity of radiation-induced mucositis in head and neck cancer patients. Mol Clin Oncol. 3:381–386.
   PubMedGoogle Scholar
• Elting LS, Cooksley CD, Chambers MS, Garden AS. 2007. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 68:1110–1120.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Kobayashi R, Suzuki A, Ishihara M, Nakamura N, Kitagawa J, Kanemura N, Kasahara S, Kitaichi K, Hara T, et al. 2014. Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation. Anticancer Res. 34:7271–7277.
   PubMed Web of Science ®Google Scholar
• Jensen SB, Jarvis V, Zadik Y, Barasch A, Ariyawardana A, Hovan A, Yarom N, Lalla RV, Bowen J, Elad S, et al. 2013. Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Support Care Cancer. 21:3223–3232.
   PubMed Web of Science ®Google Scholar
• Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, et al. 2014. Mascc/isoo clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 120:1453–1461.
   Google Scholar
• Ledoux D, Gannoun-Zaki L, Barritault D. 1992. Interactions of fgfs with target cells. Prog Growth Factor Res. 4:107–120.
   PubMedGoogle Scholar
• Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. 2003. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with behçet’s disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 4:19–28.
   PubMedGoogle Scholar
• Matsukura T, Tanaka H. 2000. Applicability of zinc complex of l-carnosine for medical use. Biochemistry Mosc. 65:817–823.
   PubMed Web of Science ®Google Scholar
• Moroni E, Dell'Era P, Rusnati M, Presta M. 2002. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res. 11:19–32.
   PubMedGoogle Scholar
• Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. 2004. Chemotherapy-induced and/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia. 6:423–431.
   PubMed Web of Science ®Google Scholar
• Nayak S, Goel MM, Makker A, Bhatia V, Chandra S, Kumar S, Agarwal SP. 2015. Fibroblast growth factor (fgf-2) and its receptors fgfr-2 and fgfr-3 may be putative biomarkers of malignant transformation of potentially malignant oral lesions into oral squamous cell carcinoma. PLoS One. 10:e0138801.
   PubMed Web of Science ®Google Scholar
• Nonzee NJ, Dandade NA, Patel U, Markossian T, Agulnik M, Argiris A, Patel JD, Kern RC, Munshi HG, Calhoun EA, et al. 2008. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 113:1446–1452.
   PubMed Web of Science ®Google Scholar
• Okumura M, Okuda T, Okamoto T, Nakamura T, Yajima M. 1996. Enhanced angiogenesis and granulation tissue formation by basic fibroblast growth factor in healing-impaired animals. Arzneimittelforschung. 46:1021–1026.
   PubMed Web of Science ®Google Scholar
• Oshitani T, Okada K, Kushima T, Suematsu T, Obayashi K, Hirata Y, Takada Y, Ishida T, Yoshida M, Narabayashi I. 1990. [Clinical evaluation of sodium alginate on oral mucositis associated with radiotherapy]. Nihon Gan Chiryo Gakkai Shi. 25:1129–1137.
   PubMedGoogle Scholar
• Radtke ML, Kolesar JM. 2005. Palifermin (kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. J Oncol Pharm Pract. 11:121–125.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J, Cesano A, Gayko U, Chen MG, Clarke S. 2006. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol. 24:5194–5200.
   PubMed Web of Science ®Google Scholar
• Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, et al. 2004. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 100(9):2026–2046.
   Web of Science ®Google Scholar
• Saunders DP, Epstein JB, Elad S, Allemano J, Bossi P, van de Wetering MD, Rao NG, Potting C, Cheng KK, Freidank A, et al. 2013. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer. 21:3191–3207.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, et al. 2001. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 19:2201–2205.
   PubMed Web of Science ®Google Scholar
• Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, et al. 2004. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 351:2590–2598.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Leinonen M, Kullenberg T, Rudebeck M, de Chateau M, Spielberger R. 2016. Long-term safety outcomes in patients with hematological malignancies undergoing autologous hematopoietic stem cell transplantation treated with palifermin to prevent oral mucositis. Biol Blood Marrow Transplant. 22:164–169.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O’Roark S, Gillenwater AM, Bueso-Ramos C, et al. 2010. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 153:358–367.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Suemaru K, Nakanishi M, Nakajima N, Tanaka M, Tanaka A, Araki H. 2014. Assessment of the hamster cheek pouch as a model for radiation-induced oral mucositis, and evaluation of the protective effects of keratinocyte growth factor using this model. Int J Radiat Biol. 90:884–891.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Ishihara M, Matsuura K, Mizuta K, Itoh Y. 2010. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int J Cancer. 127:1984–1990.
   PubMed Web of Science ®Google Scholar
• Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G, Shen L. 2015. Formononetin, a novel fgfr2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget. 6:44563–44578.
   PubMed Web of Science ®Google Scholar
• Yamamura K, Ohta S, Yano K, Yotsuyanagi T, Okamura T, Nabeshima T. 1998. Oral mucosal adhesive film containing local anesthetics: in vitro and clinical evaluation. J Biomed Mater Res. 43:313–317.
   PubMed Web of Science ®Google Scholar